Navidea Biopharmaceuticals to Announce Fourth Quarter and Full Year 2015 Results on March 23, 2016
March 21 2016 - 6:30PM
Business Wire
- Conference call with investment community
to follow at 8:00 a.m. ET -
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today
announced that the Company will report its financial results for
the fourth quarter and full-year 2015, on Wednesday, March 23, 2016
prior to a conference call with the investment community scheduled
at 8:00 a.m. ET.
Investors and the public are invited to access the live audio
webcast through the link below. Participants are encouraged to
log-in and/or dial-in fifteen minutes before the conference call
begins. The webcast replay is expected to be available on our
investor website, http://ir.navidea.com, approximately two to four
hours after the live event.
Event: Navidea Biopharmaceuticals Q4 and
Year-End 2015 Financial Results Conference Call Date/Time:
Wednesday, March 23, 2016 at 8:00 a.m. ET Webcast Link:
http://edge.media-server.com/m/p/ji54i8si
Dial-in Number – US: 1 (855) 897-5884 Dial in Number – Int’l: 1
(720) 634-2940 Participant Passcode: 56356081 Replay
A webcast replay will be available on the
Investor Relations section of our website at http://ir.navidea.com
for 30 days.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision immunodiagnostic agents and
immunotherapeutics. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. The
development activities of the Manocept immunotherapeutic platform
will be conducted by Navidea in conjunction with its subsidiary,
Macrophage Therapeutics. Navidea’s strategy is to deliver superior
growth and shareholder return by bringing to market novel products
and advancing the Company’s pipeline through global partnering and
commercialization efforts. For more information, please visit
www.navidea.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160321006393/en/
Navidea BiopharmaceuticalsInvestorsTom Baker,
617-532-0624tbaker@navidea.comorMediaSharon Correia, 978-655-2686Senior Director,
Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Sep 2023 to Sep 2024